Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817520 | 0.85 | ADORA2A (0.52) | ADORA2AADORA3ADORA1IKBKBCHUK | |
| SCHEMBL17895242 | 0.85 | ADORA2A (0.45) | ADORA2AADORA3ADORA1IKBKBCHUK | |
| SCHEMBL17895220 | 0.82 | IKBKB (0.49) | IKBKBCHUK | |
| SCHEMBL2818159 | 0.82 | ADORA2A (0.46) | ADORA2AADORA3ADORA1TLR7 | |
| SCHEMBL17895075 | 0.81 | ADORA2A (0.48) | ADORA2AADORA3ADORA1IKBKBCHUK | |
| SCHEMBL2820339 | 0.80 | ADORA2A (0.52) | ADORA2AADORA3ADORA1TLR7CSNK1A1 | |
| SCHEMBL2816282 | 0.80 | ALDH1A1 (0.48) | ADORA2AADORA3ADORA1TLR7 | |
| SCHEMBL2814962 | 0.80 | ADORA2A (0.52) | ADORA2AADORA3ADORA1 | |
| SCHEMBL2815156 | 0.80 | ADORA2A (0.55) | ADORA2AADORA3ADORA1IKBKBCHUK | |
| SCHEMBL2816944 | 0.80 | ADORA2A (0.44) | ADORA2AADORA3ADORA1IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | ADORA2A 1104/4885ADORA3 1115/4885ADORA1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.